SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics

Area of Science:

• Cellular signaling
• Molecular biology
• Oncology

Background:

• RAF kinases are central to cell signaling and disease, but their regulation, including heterodimerization and inhibitory dephosphorylation at S259, remains incompletely understood.
• The SHOC2 complex, comprising SHOC2, MRAS, and PP1, acts as a RAF S259 holophosphatase, and its dysregulation is implicated in Noonan syndrome.

Purpose of the Study:

• To elucidate the role of the SHOC2 complex in RAF activation and downstream signaling.
• To investigate context-dependent mechanisms of RAF and ERK pathway activation.
• To explore the therapeutic potential of targeting the SHOC2 complex for selective ERK pathway inhibition.

Main Methods:

• Biochemical assays to analyze RAF kinase activity and complex formation.
• Cellular experiments using EGF stimulation in DLD-1 cells.
• Investigation of RAF and ERK pathway dynamics under 2D and anchorage-independent conditions.
• Analysis of KRAS mutant cell signaling.

Main Results:

• SHOC2 complex-mediated S259 RAF dephosphorylation is essential for growth factor-induced RAF heterodimerization and MEK dissociation from BRAF.
• SHOC2-independent RAF and ERK activation mechanisms involving CRAF N-region phosphorylation were identified.
• SHOC2 is critical for rapid, transient ERK activation but not for slow, sustained phases driven by RAS proteins and CRAF.
• While SHOC2 is dispensable for 2D proliferation due to redundant pathways, KRAS mutant cells rely on SHOC2 for anchorage-independent ERK signaling.

Conclusions:

• SHOC2 plays a context-dependent role in ERK pathway dynamics, preferentially engaged by KRAS oncogenic signaling.
• The study provides a biochemical framework for targeting the SHOC2 holophosphatase for selective ERK pathway inhibition.